Advertisement
IQV or RVTY or TMO
Which Stock Would AI Choose? IQVIA Holdings (IQV) vs. Revvity (RVTY) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Scale matters: TMO dominates with a market capitalization near $200 billion and quarterly revenue exceeding $10 billion, while IQV and RVTY operate at roughly $34 billion and $12 billion, respectively, creating distinct risk-and-reward profiles.
- Divergent growth narratives: IQV benefits from a $32 billion contracted backlog and strong clinical trial demand, RVTY is navigating a turnaround with impressive software growth offset by diagnostic headwinds in China, and TMO delivers steady single-digit organic growth powered by its diversified life sciences platform.
- Valuation disparities: IQV trades at a forward P/E (price-to-earnings) ratio near 16–18x, RVTY around 21x, and TMO near 21x, reflecting different market expectations about future earnings trajectories.
- Capital allocation divergence: All three companies have been active share repurchasers, but IQV and RVTY have pursued more aggressive buyback programs relative to their size in recent quarters.
- Sector exposure shapes resilience: TMO's broad end-market diversification offers the most stability, while IQV's reliance on pharmaceutical R&D (research and development) spending and RVTY's exposure to China's hospital reimbursement shifts introduce unique risk factors.
- Momentum signals differ: Recent market activity shows TMO regaining investor confidence following a Q2 earnings beat and raised guidance, IQV steadily recovering with improving bookings momentum, and RVTY facing mixed sentiment after a guidance adjustment.
Introduction
Investors evaluating the healthcare and life sciences sector often find themselves comparing companies that operate at different points along the value chain — from clinical research services to diagnostic tools to broad scientific instrumentation. IQV, RVTY, and TMO represent three distinct yet interconnected businesses within this ecosystem. This comparison is particularly relevant for traders and investors seeking exposure to secular trends in drug development, diagnostic innovation, and laboratory sciences, while also weighing differences in scale, growth trajectory, valuation, and market sentiment. Whether the goal is capital appreciation or risk-managed portfolio construction, understanding how these three stocks compare on fundamentals and momentum provides a meaningful framework for decision-making in the current market environment.
IQV Overview and Recent Performance
IQV, or IQVIA Holdings Inc., is a leading global provider of clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries. The company operates through three primary segments: Research & Development Solutions (R&DS), Technology & Analytics Solutions (TAS), and Contract Sales & Medical Solutions (CSMS). In its most recent quarterly report, IQVIA posted revenue of approximately $4.0 billion, reflecting 5.3% year-over-year growth, with TAS revenue climbing nearly 9%. The R&DS segment recorded a contracted backlog of $32.1 billion — up 5.1% year-over-year — and quarterly net bookings reached $2.5 billion, translating into a book-to-bill ratio of 1.12x (meaning new orders exceeded revenue recognized). These demand indicators suggest a healthy and expanding pipeline. In recent weeks, market sentiment around IQV has been shaped by improving forward-looking demand metrics, including a sequential increase in net bookings and a pickup in RFP (Request for Proposal) flow. The company has also executed an aggressive share repurchase program, deploying over $1 billion in buybacks during the first half of the year, which has provided some support to the share price amid broader market volatility. The stock has traded within a wide 52-week range, reflecting both cyclical pressures on pharma R&D budgets and optimism about IQV's ability to convert its substantial backlog into revenue growth.
RVTY Overview and Recent Performance
RVTY, or Revvity, Inc., is a health sciences company that provides instruments, reagents, software, and services spanning diagnostics, life sciences research, and food testing. Formerly part of PerkinElmer, the company has repositioned itself around higher-growth, higher-margin segments, with its Signals Software platform serving as a standout performer. In its latest quarterly results, Revvity reported revenue of $720 million, representing 4% reported growth and 3% organic growth. The Life Sciences segment delivered 4% organic growth, while Diagnostics grew 2% organically. The Signals Software franchise expanded at an impressive rate exceeding 30% organically and set a new record for quarterly orders. Adjusted EPS (earnings per share) came in at $1.18, exceeding consensus expectations. However, sentiment around RVTY has been mixed in recent weeks. The company reduced its full-year organic growth outlook to a 2%–4% range, citing headwinds in its Immunodiagnostics business stemming from changes to hospital lab reimbursement policies in China. Operating margins also came under pressure due to lower volumes of high-margin diagnostic tests and unfavorable currency movements. On the capital allocation front, Revvity repurchased nearly $450 million of its own shares during the first half of the year, reducing its share count by roughly 4%. The stock's 52-week range reflects both the promise of its software-driven transformation and the near-term uncertainty tied to diagnostic segment challenges.
TMO Overview and Recent Performance
TMO, or Thermo Fisher Scientific Inc., is the world's largest scientific instrumentation and services company, serving pharmaceutical, biotech, academic, government, and industrial customers globally. With quarterly revenue of $10.85 billion — up 3% year-over-year — and a market capitalization approaching $200 billion, TMO operates at a scale that dwarfs most peers. In its most recent quarter, the company posted GAAP diluted EPS of $4.28 (up 6%) and adjusted EPS of $5.36. Management raised full-year guidance for both operating margin and EPS, citing better-than-expected tariff mitigation and operational efficiency gains driven by its PPI (Practical Process Improvement) Business System. Recurring consumables revenue represents approximately 83% of total sales, providing a highly stable revenue base. Recent market activity has reflected renewed investor confidence: the stock rallied sharply following its Q2 earnings release, posting one of its largest single-day percentage gains in over a decade. TMO also announced the expansion of its strategic partnership with Sanofi, including the acquisition of a sterile fill-finish facility in New Jersey — reinforcing its trusted-partner status with large pharmaceutical customers. While headwinds persist in academic and government end markets, as well as in China, TMO's diversified exposure across geographies and customer types has allowed it to absorb these pressures more effectively than smaller, more narrowly focused competitors.
Trending AI Robots
For traders seeking an algorithmic edge in navigating comparisons like this one, Tickeron's Trending AI Robots page offers a curated selection of AI-powered trading bots designed to identify opportunities across thousands of publicly traded tickers. Tickeron hosts hundreds of AI trading bots — each with distinct trading styles, strategies, timeframes, performance statistics, and sets of tickers they trade — but only those demonstrating the strongest alignment with current market conditions earn a place in the Trending AI Robots section. Some bots focus on short-term momentum signals, while others employ longer-duration trend-following or mean-reversion strategies. Performance metrics among featured bots can vary widely, with some historically achieving win rates well above 60% and annualized returns that materially exceed broad market benchmarks, depending on the strategy employed and risk parameters selected. Browsing the curated selection can help traders discover AI-driven approaches that match their own risk tolerance and investment horizon. Explore the Trending AI Robots page to see which strategies are currently resonating with real-time market dynamics.
Head-to-Head Comparison
Business Models and Revenue Mix: The three companies operate at different layers of the life sciences value chain. TMO is the most diversified, spanning analytical instruments, consumables, laboratory products, CDMO (Contract Development and Manufacturing Organization) services, and clinical diagnostics — with recurring consumables making up the vast majority of sales. IQV is primarily a CRO (Contract Research Organization) and healthcare data analytics provider, generating revenue from clinical trial management and technology-enabled commercial insights. RVTY sits in between, with a diagnostics and life sciences tools portfolio complemented by a high-growth software segment.
Growth Drivers and Momentum: IQV's growth is anchored by its $32 billion contracted backlog and rising biopharma R&D spending globally, with a book-to-bill ratio above 1.0x signaling sustained demand. RVTY's growth story is bifurcated: its Signals Software business is expanding rapidly (over 30% organic growth), but its Immunodiagnostics unit is contending with reimbursement-driven headwinds in China. TMO is growing at a steady 2–3% organic rate, with pharma and biotech demand offsetting softness in academic and government channels. Among the three, IQV offers the strongest near-term revenue visibility due to its backlog, while RVTY carries the highest upside potential — but also the most execution risk.
Risk Factors: IQV's risks include concentration in pharmaceutical R&D spending cycles, high leverage (net debt-to-EBITDA of approximately 3.6x), and currency exposure given its global clinical trial operations. RVTY faces China policy risk, margin compression from a shifting product mix, and integration risks tied to its ongoing transformation. TMO's primary risks include a slower-than-expected recovery in academic and government funding, persistent China softness, and tariff-related supply chain adjustments — though its scale provides a cushion that smaller peers lack.
Valuation Sensitivity: On a forward P/E basis, IQV trades at a discount to both RVTY and TMO, partially reflecting its higher leverage and exposure to pharma spending cycles. RVTY's valuation, while higher than IQV's, embeds expectations of a successful software-led margin expansion story. TMO commands a premium valuation justified by its market leadership, recurring revenue base, and consistent execution — though its forward P/E has compressed from historical averages, suggesting the market may be underappreciating its earnings power. For value-oriented investors, IQV's discounted multiple may appear attractive; for growth-focused capital, RVTY's software trajectory offers a differentiated thesis; for stability seekers, TMO's balanced profile stands out.
Tickeron AI Verdict
Based on observable factors including trend consistency, stability of demand indicators, and relative positioning in the current market environment, Tickeron's AI-driven analytical framework would likely view TMO as the most balanced candidate among the three. TMO's combination of a Q2 earnings beat, upwardly revised full-year guidance, recurring revenue resilience, and strong post-earnings price momentum creates a favorable signal profile that many AI trend-following models are designed to identify. IQV presents a compelling case with its improving book-to-bill ratio and discounted valuation, but its higher leverage and cyclical exposure introduce greater variability in trend signals. RVTY offers the most asymmetric risk-reward profile — its software growth is genuinely impressive, yet the China-driven guidance reduction and post-earnings selloff suggest that AI models emphasizing trend stability would likely adopt a more cautious stance until clearer directional signals emerge. No AI-driven assessment can guarantee outcomes, and all three stocks retain distinct strengths that may appeal to different strategy profiles depending on market conditions and individual risk parameters.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
IQV’s FA Score shows that 0 FA rating(s) are green whileRVTY’s FA Score has 2 green FA rating(s), and TMO’s FA Score reflects 2 green FA rating(s).
- IQV’s FA Score: 0 green, 5 red.
- RVTY’s FA Score: 2 green, 3 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
IQV’s TA Score shows that 4 TA indicator(s) are bullish while RVTY’s TA Score has 3 bullish TA indicator(s), and TMO’s TA Score reflects 6 bullish TA indicator(s).
- IQV’s TA Score: 4 bullish, 5 bearish.
- RVTY’s TA Score: 3 bullish, 6 bearish.
- TMO’s TA Score: 6 bullish, 4 bearish.
Price Growth
IQV (@Medical Specialties) experienced а -0.76% price change this week, while RVTY (@Medical Specialties) price change was -1.84% , and TMO (@Medical Specialties) price fluctuated +1.03% for the same time period.
The average weekly price growth across all stocks in the @Medical Specialties industry was -0.78%. For the same industry, the average monthly price growth was +12.92%, and the average quarterly price growth was +4.71%.
Reported Earning Dates
IQV is expected to report earnings on Jul 28, 2026.
RVTY is expected to report earnings on Aug 04, 2026.
TMO is expected to report earnings on Jul 23, 2026.
Industries' Descriptions
@Medical Specialties (-0.78% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
| IQV | RVTY | TMO | |
| Capitalization | 34.4B | 12.3B | 198B |
| EBITDA | 3.52B | 773M | 11.7B |
| Gain YTD | -8.496 | 14.080 | -7.923 |
| P/E Ratio | 25.62 | 52.96 | 29.27 |
| Revenue | 16.6B | 2.9B | 45.2B |
| Total Cash | 2.1B | N/A | 1.12B |
| Total Debt | 16.1B | 3.35B | 43.2B |
IQV | RVTY | TMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 83 | 81 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 62 Fair valued | 15 Undervalued | 13 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 86 | |
SMR RATING 1..100 | 42 | 89 | 62 | |
PRICE GROWTH RATING 1..100 | 42 | 44 | 47 | |
P/E GROWTH RATING 1..100 | 35 | 23 | 33 | |
SEASONALITY SCORE 1..100 | 85 | 3 | 90 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
TMO's Valuation (13) in the Medical Specialties industry is in the same range as RVTY (15) in the Medical Specialties industry, and is somewhat better than the same rating for IQV (62) in the Servicestothe Health Industry industry. This means that TMO's stock grew similarly to RVTY’s and somewhat faster than IQV’s over the last 12 months.
TMO's Profit vs Risk Rating (86) in the Medical Specialties industry is in the same range as RVTY (100) in the Medical Specialties industry, and is in the same range as IQV (100) in the Servicestothe Health Industry industry. This means that TMO's stock grew similarly to RVTY’s and similarly to IQV’s over the last 12 months.
IQV's SMR Rating (42) in the Servicestothe Health Industry industry is in the same range as TMO (62) in the Medical Specialties industry, and is somewhat better than the same rating for RVTY (89) in the Medical Specialties industry. This means that IQV's stock grew similarly to TMO’s and somewhat faster than RVTY’s over the last 12 months.
IQV's Price Growth Rating (42) in the Servicestothe Health Industry industry is in the same range as RVTY (44) in the Medical Specialties industry, and is in the same range as TMO (47) in the Medical Specialties industry. This means that IQV's stock grew similarly to RVTY’s and similarly to TMO’s over the last 12 months.
RVTY's P/E Growth Rating (23) in the Medical Specialties industry is in the same range as TMO (33) in the Medical Specialties industry, and is in the same range as IQV (35) in the Servicestothe Health Industry industry. This means that RVTY's stock grew similarly to TMO’s and similarly to IQV’s over the last 12 months.
| IQV | RVTY | TMO | |
|---|---|---|---|
| RSI ODDS (%) | 3 days ago 56% | 3 days ago 73% | 3 days ago 61% |
| Stochastic ODDS (%) | 3 days ago 67% | 3 days ago 66% | 3 days ago 59% |
| Momentum ODDS (%) | 3 days ago 71% | 3 days ago 74% | 3 days ago 64% |
| MACD ODDS (%) | 3 days ago 73% | 3 days ago 67% | 3 days ago 60% |
| TrendWeek ODDS (%) | 3 days ago 65% | 3 days ago 67% | 3 days ago 61% |
| TrendMonth ODDS (%) | 3 days ago 63% | 3 days ago 61% | 3 days ago 61% |
| Advances ODDS (%) | 18 days ago 59% | 4 days ago 64% | 4 days ago 61% |
| Declines ODDS (%) | 7 days ago 65% | 7 days ago 67% | 12 days ago 63% |
| BollingerBands ODDS (%) | 3 days ago 53% | 3 days ago 75% | 3 days ago 59% |
| Aroon ODDS (%) | 3 days ago 43% | 3 days ago 54% | 3 days ago 59% |
Advertisement
IQV and
Correlation & Price change
A.I.dvisor indicates that over the last year, IQV has been closely correlated with CRL. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if IQV jumps, then CRL could also see price increases.
| Ticker / NAME | Correlation To IQV | 1D Price Change % | ||
|---|---|---|---|---|
| IQV | 100% | -2.01% | ||
| CRL - IQV | 74% Closely correlated | -2.10% | ||
| TMO - IQV | 71% Closely correlated | -1.97% | ||
| MEDP - IQV | 65% Loosely correlated | -0.04% | ||
| RVTY - IQV | 64% Loosely correlated | -1.33% | ||
| A - IQV | 62% Loosely correlated | -3.41% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 80% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.